Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
50 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Program
On WRAL at 5: Storms moving in on DualDoppler5000 radar. How long severe weather threats last tonight
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,085.62
-9.37 (-0.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
38
39
Next >
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
February 21, 2023
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.
Via
Investor's Business Daily
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
February 21, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Top Healthcare Stocks Defying the Bear Market
February 14, 2023
These companies have impeccable long-term investment theses.
Via
The Motley Fool
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
February 13, 2023
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.
Via
Talk Markets
2 Biotech Stocks That Could Help Set You Up for Life
February 11, 2023
The two companies have seen similar share growth over the past year.
Via
The Motley Fool
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
February 03, 2023
Via
Benzinga
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
February 13, 2023
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.
Via
InvestorPlace
New 52-Week Highs In 2023
February 13, 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023.
Via
Talk Markets
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
February 13, 2023
Via
Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
February 10, 2023
Via
Benzinga
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
February 08, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Pharmaceuticals's Earnings Outlook
February 02, 2023
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 01, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
January 30, 2023
Via
Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
February 07, 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.
Via
InvestorPlace
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
February 03, 2023
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.
Via
Investor's Business Daily
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
February 03, 2023
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...
Via
Benzinga
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
February 03, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
The 7 Most Undervalued Stocks to Buy in February 2023
February 02, 2023
These undervalued stocks to buy are under-appreciated, and have substantial upside as we move deeper into the new year.
Via
InvestorPlace
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
February 02, 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.
Via
InvestorPlace
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
February 01, 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.
Via
InvestorPlace
Regeneron Announces Investor Conference Presentations
January 31, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
January 30, 2023
Via
Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
January 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.